Education• August 12, 2026• 8 min read

You Got a Biopsy Result. Should You Get a Second Opinion?

Medically Reviewed by Dr. Marcus Vance, Chief Medical Officer & Clinical Lead on 2026-08-12. Adheres to strict medical communication criteria.

Dr. Elena Rostova, MD, PhD

Chief Medical Officer at Premedice Systems

Summary & Key Takeaway

A second pathology opinion changes the diagnosis in roughly 10–20% of cancer biopsy cases, and in some complex specialties like bone and soft-tissue pathology, that number climbs to 25%. If your biopsy result will determine whether you undergo chemotherapy, surgery, or watchful waiting, getting another pathologist to review the slide is not a sign of distrust. It is a clinical safety check. This article explains when a second opinion is strongly recommended, how to request one, and how AI-assisted pathology tools are making the process faster and more accessible than ever.

✳︎ Core Insights

Independent pathology review changes the original diagnosis in approximately 10–20% of cancer cases, according to multiple peer-reviewed studies.
Disagreement rates are highest in complex subspecialties: bone tumors (25%), brain tumors (up to 30%), and melanocytic skin lesions (up to 37%).
Most pathology departments accept second-opinion requests, and your referring physician can initiate the review by sending slides and reports to an independent specialist.
Digital slide scanning and AI-assisted tools now allow remote second opinions without physically shipping glass slides between institutions.
A second opinion does not delay treatment in most cases; pathology review typically takes 3–10 business days and can run in parallel with treatment planning.

Why Biopsy Diagnoses Disagree More Than Patients Expect

Pathology is the gold standard for tissue diagnosis, but it is not infallible. A 2017 systematic review published in JAMA found that second-opinion review changed the original diagnosis in approximately 10–20% of cancer cases referred to academic medical centers. In roughly half of those changes, the original diagnosis was benign and the second opinion found malignancy, or vice versa. The gap is not a failure of individual pathologists; it reflects the genuine difficulty of interpreting tissue under a microscope, especially when the sample is small, fragmented, or from an unusual anatomical site.

The degree of disagreement varies by specialty. Bone and soft-tissue pathology shows discordance rates up to 25% because many tumors share overlapping cellular features. Dermatopathology disagreement on melanocytic lesions can reach 37% in some studies, driven by the spectrum between benign nevi and melanoma. Brain tumor subtyping, particularly for gliomas, shows discordance in up to 30% of cases. For common cancers like breast and colorectal carcinoma, the agreement rate is substantially higher, but the consequences of a wrong call are also proportionally larger.

The Clinical Scenarios Where a Second Opinion Matters Most

Certain biopsy contexts practically demand an independent review. A new cancer diagnosis before any treatment begins is the most straightforward case. If the biopsy says you have cancer but the treatment plan involves major surgery, toxic chemotherapy, or lifelong medication, a second read of the same slide is prudent. This is especially true for rare cancers where the treating oncologist may never have seen that exact subtype before. Our guide on when should you get a second opinion covers the full decision framework across imaging, lab results, and tissue diagnosis.

A benign result in a high-suspicion scenario also warrants review. When imaging strongly suggests malignancy but the biopsy comes back negative or benign, the discordance between clinical suspicion and pathology may indicate a sampling error or a reading miss. The same logic applies when an MRI report and a biopsy result point in different directions, as explained in our analysis of second-opinion MRI reports. Similarly, a borderline or indeterminate result where the pathologist uses words like "atypical," "suspicious," or "cannot exclude" is explicitly acknowledging diagnostic uncertainty. These are cases where a fresh set of expert eyes has the highest probability of adding value.

How to Request a Pathology Second Opinion

The process is straightforward in most health systems. Contact your referring physician or surgeon and request an independent pathology review. They can write a referral and send your glass slides and pathology report to a specialist at an academic medical center or a subspecialty pathologist. Many institutions have formal second-opinion programs, and some even maintain panels of fellowship-trained pathologists specifically for this purpose.

If you are navigating the process yourself, several tools make it easier. The ability to translate complex pathology language into plain English helps you understand what the original report actually says before seeking review. Digital pathology platforms now allow hospitals to scan slides at high resolution and transmit them electronically, eliminating the risk of shipping fragile glass slides. Some services even use AI-assisted tools to pre-screen slides and route them to the most relevant subspecialist, as explored in our overview of AI medical second opinions.

What Happens During an Independent Pathology Review

During a second-opinion review, an independent pathologist examines the same slides and, in some cases, requests additional stains or molecular testing. They compare their findings against the original report and issue a formal concurrence or disagreement. If the second pathologist disagrees, they typically provide a detailed explanation of their reasoning, which your treating physician uses to adjust the diagnosis or request further testing.

The review does not replace the original pathologist's work. It adds a layer of validation. In roughly 80–90% of cases, the second pathologist agrees with the original diagnosis, which confirms that the initial reading was accurate. In the 10–20% where disagreement occurs, the revision can range from a minor reclassification that does not change treatment, to a completely different diagnosis that fundamentally alters the care plan. Understanding why two pathologists read the same slide differently requires the same analytical framework we explain in our article on why two doctors read the same lab results differently.

When AI-Assisted Pathology Changes the Second-Opinion Equation

The traditional second-opinion process depended on geographic proximity to a subspecialty center. That constraint is dissolving. Digital slide scanning lets institutions capture whole-slide images at diagnostic resolution, and AI tools can pre-analyze those images to flag areas of concern, measure tumor boundaries, or suggest differential diagnoses. When a second opinion is needed from a subspecialty pathologist in another city or country, the combination of digital slides and AI triage makes the review feasible within days rather than weeks.

This is not about AI replacing the pathologist. It is about AI accelerating the logistics of expert consultation. A second-opinion service augmented by AI can route a rare bone tumor slide directly to a musculoskeletal pathology fellow, or flag a melanocytic lesion for a dermatopathologist, without requiring a generalist to triage first. The result is faster turnaround, more targeted expertise, and a second-opinion process that works the same whether the expert is across the hall or across an ocean.

What a Second Opinion Costs and Whether Insurance Covers It

Out-of-pocket costs for a pathology second opinion vary by institution and insurance plan. At many academic medical centers, the fee for an independent pathology review ranges from $200 to $800, depending on whether additional immunohistochemical stains or molecular tests are needed. Some hospitals bundle the second-opinion review into their diagnostic workup at no extra charge if you are being treated there.

Insurance coverage depends on your plan and whether the second opinion is deemed medically necessary. Most insurers cover a second pathology opinion when the original diagnosis is ambiguous, when the case involves a rare cancer, or when treatment planning requires confirmation. Contact your insurance provider before the review to clarify coverage. If cost is a barrier, ask about telepathology services, which often charge less because they eliminate the physical logistics of slide transport.

How Second-Opinion Data Improves Diagnostic Accuracy Across the System

Individual second opinions benefit the patient directly, but the aggregate data benefits everyone. When pathology departments track their concordance rates with external reviewers, they identify systematic patterns: certain tissue types that are consistently under-read, staining protocols that introduce ambiguity, or subspecialty gaps in training. Institutions that maintain robust second-opinion programs typically show higher diagnostic accuracy over time because the feedback loop catches drift before it compounds.

AI models trained on pathology data also benefit from second-opinion datasets. The labeled disagreements between pathologists create training signals that help algorithms learn where human interpretation diverges most, and where computational tools can provide the most value as a safety net. Studies have shown that AI-assisted pathology review can reduce inter-observer variability by 15–25% in select tissue types, effectively raising the baseline agreement before a human expert even sees the slide.

Continue Reading

Education

Why a Second Opinion Costs $400 — and How AI Makes It Free

Education

How Much Does a Second Opinion Cost? (2026 Benchmarks)

About the Author

Dr. Elena Rostova, MD, PhD

Clinician-researcher with 14 years in clinical informatics and ML evaluation for healthcare systems.

Expert Takeaway

When a biopsy result will guide surgery, chemotherapy, or radiation, an independent pathology review is a reasonable and well-supported safety step. It costs modestly in time but can prevent the substantial downstream cost of treating the wrong disease.

QFrequently Asked Questions

Q1How often does a second pathology opinion change the diagnosis?

In peer-reviewed studies, an independent second opinion changes the original biopsy diagnosis in approximately 10–20% of cancer cases. The rate is higher—up to 25–37%—for complex subspecialties like bone tumors, brain tumors, and melanocytic skin lesions, and lower for common cancers like breast and colorectal carcinoma.

Q2Can I get a second opinion on my biopsy without changing doctors?

Yes. Most pathology departments accept second-opinion requests through your current physician, who sends your slides and reports to an independent pathologist. You do not need to change your treating doctor to get a second read. Some patients also contact academic medical centers directly for their second-opinion programs.

Q3How long does a pathology second opinion take?

A standard pathology second opinion takes 3–10 business days, depending on whether additional stains or molecular tests are needed. Digital slide transmission and AI-assisted routing can reduce turnaround to 2–5 days for straightforward cases. If urgent, ask your physician to note the clinical urgency on the referral.

Q4Does insurance cover a second pathology opinion?

Most insurance plans cover a second opinion when the original diagnosis is ambiguous, the cancer is rare, or treatment confirmation is needed. Coverage varies by plan, so verify with your insurer before the review. Academic medical centers often have financial counselors who can help navigate coverage questions.

Q5What is the difference between a second opinion and a pathology consultation?

A second opinion is an independent review where a pathologist forms their own diagnosis from your slides, often without seeing the original report first. A consultation is when a pathologist reviews slides at the request of the original pathologist to provide input on a specific question. Both add value, but a second opinion is the stronger verification.